Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TROPION-LUNG01: Datopotamab Deruxtecan vs Docetaxel in Previously Treated Advanced or Metastatic NSCLC
NCT04656652Phase 3Active, not recruiting
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Dec 2020
- Primary completion
- May 2024
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 26
01
Overview
A Phase 3 trial of datopotamab deruxtecan in non-small cell lung cancer (NSCLC), sponsored by Daiichi Sankyo Co., Ltd.. Started Dec 2020; status: active, not recruiting.
02
Drugs
datopotamab deruxtecan
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04656652.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04656652.